Literature DB >> 6332630

Elevation of von Willebrand factor is independent of erythrocyte sedimentation rate and persists after glucocorticoid treatment in giant cell arteritis.

A B Federici, R I Fox, L R Espinoza, T S Zimmerman.   

Abstract

Von Willebrand factor (vWF) antigen levels were measured in 39 patients with biopsy-proven giant cell arteritis (GCA), 16 patients with polymyalgia rheumatica (PMR), 12 patients with Sjögren's syndrome, and 7 with choroiditis, as well as in 20 age- and sex-matched controls. Among GCA patients, 31 (group A) had clinically inactive disease and were taking low-dose glucocorticoids for at least 1 year; their vWF levels were high even in the presence of a normalized erythrocyte sedimentation rate (ESR). When the ESR and vWF were analyzed in another 8 GCA patients (group B) before and after treatment with glucocorticoids, vWF remained elevated even though the ESR returned to normal. Among the highest levels of vWF were those of 3 GCA patients who presented with ocular symptoms and positive temporal artery biopsies, but normal ESR. The presence of elevated vWF was not specific for GCA since elevated levels were also found in patients with PMR, Sjögren's syndrome, and choroiditis. The levels of vWF in GCA were significantly higher (P less than 0.01) than in these other conditions associated with myalgias and eye symptoms. Elevation of vWF levels may help in the differential diagnosis of GCA, particularly when the ESR is normal and ocular symptoms are present.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6332630     DOI: 10.1002/art.1780270912

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  12 in total

1.  von Willebrand factor antigen in giant cell arteritis.

Authors:  A J Farrell; D R Blake
Journal:  Ann Rheum Dis       Date:  1992-10       Impact factor: 19.103

2.  Damage to the endothelium in Sjögren's syndrome: lack of correlation with antinuclear antibody titre and presence of antibodies to SSA or SSB autoantigens.

Authors:  A D Blann; A C Wainwright; P Emery
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

3.  Plasminogen activator inhibitor and von Willebrand factor in polymyalgia rheumatica.

Authors:  A Uddhammar; S Rantapåå-Dahlqvist; T K Nilsson
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

4.  Von Willebrand factor in the outcome of temporal arteritis.

Authors:  M C Cid; J Monteagudo; J Oristrell; J Vilaseca; L Pallarés; R Cervera; C Font; J Font; M Ingelmo; A Urbano-Márquez
Journal:  Ann Rheum Dis       Date:  1996-12       Impact factor: 19.103

5.  Roles of claudin-5 and von Willebrand factor in patients with rheumatoid arthritis.

Authors:  Gönül Gurol; Ihsan Hakkı Ciftci; Halil Harman; Engin Karakece; Ayhan Kamanli; Ibrahim Tekeoglu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

6.  Factor VIII related antigen in the assessment of vasculitis.

Authors:  A D Woolf; G Wakerley; T B Wallington; D G Scott; P A Dieppe
Journal:  Ann Rheum Dis       Date:  1987-06       Impact factor: 19.103

7.  Endothelial cell derived factors in relation to antibodies to SSA or SSB and to endothelial cells in Sjögren's syndrome.

Authors:  S Rantapää-Dahlqvist; T K Nilsson
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

8.  von Willebrand factor antigen and plasminogen activator inhibitor in giant cell arteritis.

Authors:  E Nordborg; R Andersson; L Tengborn; S Edén; B A Bengtsson
Journal:  Ann Rheum Dis       Date:  1991-05       Impact factor: 19.103

9.  Serum concentrations of von Willebrand factor and soluble thrombomodulin indicate alteration of endothelial function in inflammatory bowel diseases.

Authors:  A M Sawyerr; M S Smith; A Hall; M Hudson; C R Hay; A J Wakefield; M G Brook; H Tomura; R E Pounder
Journal:  Dig Dis Sci       Date:  1995-04       Impact factor: 3.199

10.  von Willebrand factor antigen compared with other factors in vasculitic syndromes.

Authors:  E Ateş; A Bakkaloğlu; U Saatçi; O Söylemezoğlu
Journal:  Arch Dis Child       Date:  1994-01       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.